<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15486">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00145574</url>
  </required_header>
  <id_info>
    <org_study_id>WEL-410</org_study_id>
    <nct_id>NCT00145574</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients With Heterozygous Familial Hypercholesterolemia on a Stable Dose of Statins or Treatment Naive to Lipid-lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Austria: Federal Ministry for Health and Women</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <authority>New Zealand: Medsafe (New Zealand Medicines and Medical Devices Safety Authority)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the lipid-lowering effect and safety of colesevelam therapy
      administered to heterozygous familial pediatric patients 10 through 17 years of age who are
      on a stable dose of a pediatric-approved statin monotherapy (atorvastatin, lovastatin,
      simvastatin or pravastatin), or who are treatment naive to lipid-lowering therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C) From Day 1 (Study Baseline) to Week 8.</measure>
    <time_frame>8 weeks (week 8 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in LDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline)to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Total Cholesterol (TC) From Day 1 (Study Baseline) to Week 8.</measure>
    <time_frame>8 weeks (week 8 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in total cholesterol (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Triglycerides (TG) From Day 1 (Study Baseline) to Week 8.</measure>
    <time_frame>8 weeks (week 8 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in triglycerides (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma High-density Lipoprotein-cholesterol (HDL-C) From Day 1 (Study Baseline) to Week 8.</measure>
    <time_frame>8 weeks (week 8 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in HDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Non-high Density Lipoprotein-cholesterol (Non-HDL-C) From Day 1 (Study Baseline) to Week 8.</measure>
    <time_frame>8 weeks (week 8 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in non-HDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Apolipoprotien A-I (Apo A-1) From Day 1 (Study Baseline) to Week 8.</measure>
    <time_frame>8 weeks (week 8 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in Apolipoprotien A-I (Apo A-1) (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma Apolipoprotein B (Apo B) From Day 1 (Study Baseline) to Week 8.</measure>
    <time_frame>8 weeks (week 8 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in Apo B (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Study Baseline (Day 1) to Week 26.</measure>
    <time_frame>26 weeks (week 26 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in low-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol From Study Baseline (Day 1) to Week 26.</measure>
    <time_frame>26 weeks (week 26 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in total cholesterol (TC) from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Study Baseline (Day 1) to Week 26.</measure>
    <time_frame>26 weeks (week 26 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in triglycerides from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Study Baseline (Day 1) to Week 26.</measure>
    <time_frame>26 weeks (week 26 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in high-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-high-density Lipoprotein Cholesterol From Study Baseline (Day 1) to Week 26.</measure>
    <time_frame>26 weeks (week 26 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in non-high-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein A-I From Study Baseline (Day 1) to Week 26.</measure>
    <time_frame>26 weeks (week 26 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in apolipoprotein A-I from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein B From Study Baseline (Day 1) to Week 26.</measure>
    <time_frame>26 weeks (week 26 - day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in apolipoprotein B from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>high dose colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colesevelam HCl 3.750 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose colesevelam 1.875 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colesevelam HCl</intervention_name>
    <description>Tablets</description>
    <arm_group_label>high dose colesevelam</arm_group_label>
    <arm_group_label>Low dose colesevelam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching Tablets</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients

          -  Ages 10 to 17 years inclusive

          -  Diagnosis of heterozygous familial hypercholesterolemia

          -  On a stable dose of statin monotherapy or are treatment naive to lipid- lowering
             agents

          -  On a low-cholesterol diet

        Exclusion Criteria:

          -  Patients should not have serious concomitant conditions that could interfere with the
             analysis of the results or that could interfere with the well-being of the patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown NSW</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stefoy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kefer Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Observatory</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tygerberg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <lastchanged_date>April 8, 2010</lastchanged_date>
  <firstreceived_date>September 1, 2005</firstreceived_date>
  <firstreceived_results_date>November 6, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Michael Melino</name_title>
    <organization>Daiichi Sankyo</organization>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>colesevelam</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colesevelam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted at 41 clinical sites; Australia (1 site), Austria (1 site), Canada (5 sites), Hungary (1 site), Israel (5 sites), New Zealand (1 site), Norway (2 sites), Slovakia (3 sites), South Africa (4 sites), Czech Republic (3 sites), Netherlands (2 sites), and USA (13 sites). Study initiated November 5, 2005 completed December 18, 2007.</recruitment_details>
      <pre_assignment_details>Period I Run-In (4 weeks): Period I was a single-blind stabilization period prior to randomization. All subjects received 6 placebo tablets daily. Objective was to evaluate dosing compliance and tolerability to the tablets prior to randomization. Subjects could be on stable pediatric approved statin regimen and low cholesterol diet for 6 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo similar to active</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Colesevelam</title>
          <description>Low dose colesevelam 1.9 grams per day</description>
        </group>
        <group group_id="P3">
          <title>High Dose Colesevelam</title>
          <description>High dose colesevelam 3.8 grams per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double Blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>required restricted medicine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Long-term Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="184">2 participants discontinued after completing double-blind but before starting open label.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="173"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>required restricted medicine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo similar to active</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Colesevelam</title>
          <description>Low dose colesevelam 1.9 grams per day</description>
        </group>
        <group group_id="B3">
          <title>High Dose Colesevelam</title>
          <description>High dose colesevelam 3.8 grams per day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
                <measurement group_id="B2" value="65"/>
                <measurement group_id="B3" value="64"/>
                <measurement group_id="B4" value="194"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
                <measurement group_id="B2" value="65"/>
                <measurement group_id="B3" value="64"/>
                <measurement group_id="B4" value="194"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14.3" spread="1.74"/>
                <measurement group_id="B2" value="14.1" spread="2.19"/>
                <measurement group_id="B3" value="13.9" spread="2.0"/>
                <measurement group_id="B4" value="14.1" spread="1.98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="24"/>
                <measurement group_id="B4" value="71"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="40"/>
                <measurement group_id="B4" value="123"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Austria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>South Africa</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Israel</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="16"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Norway</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Netherlands</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hungary</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>New Zealand</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Slovakia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Czech Republic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Statin Status</title>
          <description>Non-naive refers to the number of participants who are taking statins. Naive refers to the number of participants who are not taking statins.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>non-naive</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="49"/>
                <measurement group_id="B4" value="147"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>naive</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="47"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Tanner Stage</title>
          <description>Tanner Stage represents a scale measuring physical development in children based on primary and secondary sexual characteristics. The scale has five stages, with Stage I representing prepuberty and Stage 5 representing adult physical development. Please refer to Tanner, JM; Growth at Adolescence, @nd ed. Oxford, England, Blackwell Scientific Publications, 1962 for complete definitions of each Tanner Stage of development.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>I</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>II</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>III</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="52"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>IV</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="62"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>V</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (BMI) kg/m2</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21.9" spread="4.30"/>
                <measurement group_id="B2" value="23.4" spread="6.14"/>
                <measurement group_id="B3" value="22.2" spread="4.75"/>
                <measurement group_id="B4" value="22.5" spread="5.14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>height</title>
          <description>height in centimeters (cm)</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="164.8" spread="10.35"/>
                <measurement group_id="B2" value="160.7" spread="10.90"/>
                <measurement group_id="B3" value="162.1" spread="11.94"/>
                <measurement group_id="B4" value="162.5" spread="11.16"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>weight</title>
          <description>mean weight in kilograms (kg) and standard deviation (SD)</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.3" spread="15.32"/>
                <measurement group_id="B2" value="61.5" spread="20.77"/>
                <measurement group_id="B3" value="59.0" spread="16.81"/>
                <measurement group_id="B4" value="60.3" spread="17.72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C) From Day 1 (Study Baseline) to Week 8.</title>
        <description>Percent change in LDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline)to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
        <time_frame>8 weeks (week 8 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat Population for Double blind Period. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo similar to active</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>Low dose colesevelam 1.9 grams per day</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>High dose colesevelam 3.8 grams per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C) From Day 1 (Study Baseline) to Week 8.</title>
            <description>Percent change in LDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline)to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.9" spread="16.46"/>
                  <measurement group_id="O2" value="-3.7" spread="18.36"/>
                  <measurement group_id="O3" value="-10.6" spread="19.36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary null hypotheses were tested sequentially in the following order: 1) no difference between the high-dose colesevelam HCl and placebo for percent change in LDL-C from study baseline to Week 8 endpoint with the last observation carried forward (LOCF) and 2) no difference between the low-dose colesevelam HCl and placebo for percent change in LDL-C from study baseline to Week 8 endpoint with LOCF. The hypotheses were tested at a 2-sided significance level of 5%.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1122</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Plasma Total Cholesterol (TC) From Day 1 (Study Baseline) to Week 8.</title>
        <description>Percent change in total cholesterol (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
        <time_frame>8 weeks (week 8 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat Population for Double blind Period. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo similar to active</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>Low dose colesevelam 1.9 grams per day</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>High dose colesevelam 3.8 grams per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Plasma Total Cholesterol (TC) From Day 1 (Study Baseline) to Week 8.</title>
            <description>Percent change in total cholesterol (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.9" spread="13.29"/>
                  <measurement group_id="O2" value="-1.1" spread="14.22"/>
                  <measurement group_id="O3" value="-5.4" spread="15.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5260</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0085</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Plasma Triglycerides (TG) From Day 1 (Study Baseline) to Week 8.</title>
        <description>Percent change in triglycerides (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
        <time_frame>8 weeks (week 8 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat Population for Double blind Period. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo similar to active</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>Low dose colesevelam 1.9 grams per day</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>High dose colesevelam 3.8 grams per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Plasma Triglycerides (TG) From Day 1 (Study Baseline) to Week 8.</title>
            <description>Percent change in triglycerides (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12.5" spread="40.8"/>
                  <measurement group_id="O2" value="16.9" spread="35.7"/>
                  <measurement group_id="O3" value="12.5" spread="53.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Plasma High-density Lipoprotein-cholesterol (HDL-C) From Day 1 (Study Baseline) to Week 8.</title>
        <description>Percent change in HDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
        <time_frame>8 weeks (week 8 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat Population for Double blind Period. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo similar to active</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>Low dose colesevelam 1.9 grams per day</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>High dose colesevelam 3.8 grams per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Plasma High-density Lipoprotein-cholesterol (HDL-C) From Day 1 (Study Baseline) to Week 8.</title>
            <description>Percent change in HDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.5" spread="12.52"/>
                  <measurement group_id="O2" value="3.9" spread="12.45"/>
                  <measurement group_id="O3" value="8.5" spread="14.72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0155</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Plasma Non-high Density Lipoprotein-cholesterol (Non-HDL-C) From Day 1 (Study Baseline) to Week 8.</title>
        <description>Percent change in non-HDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
        <time_frame>8 weeks (week 8 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat Population for Double blind Period. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo similar to active</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>Low dose colesevelam 1.9 grams per day</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>High dose colesevelam 3.8 grams per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                  <measurement group_id="O2" value="63"/>
                  <measurement group_id="O3" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Plasma Non-high Density Lipoprotein-cholesterol (Non-HDL-C) From Day 1 (Study Baseline) to Week 8.</title>
            <description>Percent change in non-HDL-C (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.4" spread="16.01"/>
                  <measurement group_id="O2" value="-2.1" spread="17.32"/>
                  <measurement group_id="O3" value="-8.4" spread="18.28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.3482</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Plasma Apolipoprotien A-I (Apo A-1) From Day 1 (Study Baseline) to Week 8.</title>
        <description>Percent change in Apolipoprotien A-I (Apo A-1) (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
        <time_frame>8 weeks (week 8 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) Population in Double blind Period. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo similar to active</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>Low dose colesevelam 1.9 grams per day</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>High dose colesevelam 3.8 grams per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="62"/>
                  <measurement group_id="O3" value="61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Plasma Apolipoprotien A-I (Apo A-1) From Day 1 (Study Baseline) to Week 8.</title>
            <description>Percent change in Apolipoprotien A-I (Apo A-1) (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.4" spread="14.62"/>
                  <measurement group_id="O2" value="7.0" spread="13.96"/>
                  <measurement group_id="O3" value="11.2" spread="16.79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Plasma Apolipoprotein B (Apo B) From Day 1 (Study Baseline) to Week 8.</title>
        <description>Percent change in Apo B (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
        <time_frame>8 weeks (week 8 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) Population in Double blind Period. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo similar to active</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>Low dose colesevelam 1.9 grams per day</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>High dose colesevelam 3.8 grams per day</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="62"/>
                  <measurement group_id="O3" value="61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Plasma Apolipoprotein B (Apo B) From Day 1 (Study Baseline) to Week 8.</title>
            <description>Percent change in Apo B (mg/dL) and standard deviation (SD) from Day 1 (Study Baseline) to Week 8 (last observation carried forward - LOCF)- Intent-to-Treat ITT population.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" spread="14.78"/>
                  <measurement group_id="O2" value="-0.7" spread="16.52"/>
                  <measurement group_id="O3" value="-7.0" spread="14.45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.7433</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Study Baseline (Day 1) to Week 26.</title>
        <description>Percent change in low-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
        <time_frame>26 weeks (week 26 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) Population. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to placebo treatment during the Double blind Period.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to low dose colesevelam 1.9 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to high dose colesevelam 3.8 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O4">
            <title>All High Dose Colesevelam in Open Label Extension</title>
            <description>Open Label Extension was an 18 week open-label treatment period. All participants were treated with 3750 mg colesevelam (high-dose).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="60"/>
                  <measurement group_id="O4" value="178"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Study Baseline (Day 1) to Week 26.</title>
            <description>Percent change in low-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-11.9" spread="22.39"/>
                  <measurement group_id="O2" value="-16.8" spread="19.85"/>
                  <measurement group_id="O3" value="-13.5" spread="21.58"/>
                  <measurement group_id="O4" value="-14.0" spread="21.32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol From Study Baseline (Day 1) to Week 26.</title>
        <description>Percent change in total cholesterol (TC) from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
        <time_frame>26 weeks (week 26 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to placebo treatment during the Double blind Period.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to low dose colesevelam 1.9 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to high dose colesevelam 3.8 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O4">
            <title>All High Dose Colesevelam in Open Label Extension</title>
            <description>Open Label Extension was an 18 week open-label treatment period. All participants were treated with 3750 mg colesevelam (high-dose).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="60"/>
                  <measurement group_id="O4" value="178"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Total Cholesterol From Study Baseline (Day 1) to Week 26.</title>
            <description>Percent change in total cholesterol (TC) from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-7.5" spread="17.21"/>
                  <measurement group_id="O2" value="-9.1" spread="16.91"/>
                  <measurement group_id="O3" value="-7.5" spread="17.55"/>
                  <measurement group_id="O4" value="-8.0" spread="17.15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Study Baseline (Day 1) to Week 26.</title>
        <description>Percent change in triglycerides from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
        <time_frame>26 weeks (week 26 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to placebo treatment during the Double blind Period.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to low dose colesevelam 1.9 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to high dose colesevelam 3.8 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O4">
            <title>All High Dose Colesevelam in Open Label Extension</title>
            <description>Open Label Extension was an 18 week open-label treatment period. All participants were treated with 3750 mg colesevelam (high-dose).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="60"/>
                  <measurement group_id="O4" value="178"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Triglycerides From Study Baseline (Day 1) to Week 26.</title>
            <description>Percent change in triglycerides from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-5.3" spread="59.1"/>
                  <measurement group_id="O2" value="19.5" spread="58.0"/>
                  <measurement group_id="O3" value="14.2" spread="64.5"/>
                  <measurement group_id="O4" value="11.5" spread="61.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Study Baseline (Day 1) to Week 26.</title>
        <description>Percent change in high-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
        <time_frame>26 weeks (week 26 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to placebo treatment during the Double blind Period.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to low dose colesevelam 1.9 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to high dose colesevelam 3.8 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O4">
            <title>All High Dose Colesevelam in Open Label Extension</title>
            <description>Open Label Extension was an 18 week open-label treatment period. All participants were treated with 3750 mg colesevelam (high-dose).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="60"/>
                  <measurement group_id="O4" value="178"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Study Baseline (Day 1) to Week 26.</title>
            <description>Percent change in high-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.6" spread="13.64"/>
                  <measurement group_id="O2" value="8.5" spread="20.33"/>
                  <measurement group_id="O3" value="9.3" spread="19.37"/>
                  <measurement group_id="O4" value="8.1" spread="17.86"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-high-density Lipoprotein Cholesterol From Study Baseline (Day 1) to Week 26.</title>
        <description>Percent change in non-high-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
        <time_frame>26 weeks (week 26 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to placebo treatment during the Double blind Period.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to low dose colesevelam 1.9 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to high dose colesevelam 3.8 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O4">
            <title>All High Dose Colesevelam in Open Label Extension</title>
            <description>Open Label Extension was an 18 week open-label treatment period. All participants were treated with 3750 mg colesevelam (high-dose).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="60"/>
                  <measurement group_id="O4" value="177"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Non-high-density Lipoprotein Cholesterol From Study Baseline (Day 1) to Week 26.</title>
            <description>Percent change in non-high-density lipoprotein cholesterol from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-10.0" spread="21.04"/>
                  <measurement group_id="O2" value="-13.2" spread="19.9"/>
                  <measurement group_id="O3" value="-11.0" spread="20.80"/>
                  <measurement group_id="O4" value="-11.3" spread="20.53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein A-I From Study Baseline (Day 1) to Week 26.</title>
        <description>Percent change in apolipoprotein A-I from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
        <time_frame>26 weeks (week 26 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to placebo treatment during the Double blind Period.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to low dose colesevelam 1.9 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to high dose colesevelam 3.8 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O4">
            <title>All High Dose Colesevelam in Open Label Extension</title>
            <description>Open Label Extension was an 18 week open-label treatment period. All participants were treated with 3750 mg colesevelam (high-dose).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="52"/>
                  <measurement group_id="O3" value="57"/>
                  <measurement group_id="O4" value="161"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Apolipoprotein A-I From Study Baseline (Day 1) to Week 26.</title>
            <description>Percent change in apolipoprotein A-I from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.7" spread="12.95"/>
                  <measurement group_id="O2" value="4.9" spread="14.86"/>
                  <measurement group_id="O3" value="7.2" spread="15.34"/>
                  <measurement group_id="O4" value="5.6" spread="14.40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein B From Study Baseline (Day 1) to Week 26.</title>
        <description>Percent change in apolipoprotein B from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
        <time_frame>26 weeks (week 26 - day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population. Last Observation Carried Forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to placebo treatment during the Double blind Period.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to low dose colesevelam 1.9 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O3">
            <title>High Dose Colesevelam</title>
            <description>A subpopulation of the All High Dose treatment regimen of the Open Label Extension period of participants who were randomized to high dose colesevelam 3.8 grams per day treatment during the Double blind Period.</description>
          </group>
          <group group_id="O4">
            <title>All High Dose Colesevelam in Open Label Extension</title>
            <description>Open Label Extension was an 18 week open-label treatment period. All participants were treated with 3750 mg colesevelam (high-dose).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="52"/>
                  <measurement group_id="O3" value="57"/>
                  <measurement group_id="O4" value="161"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Apolipoprotein B From Study Baseline (Day 1) to Week 26.</title>
            <description>Percent change in apolipoprotein B from baseline to Week 26 was calculated for subpopulations representing each assigned treatment group during the Double blind Period, and for the overall population in the Open Label Extension Period.</description>
            <units>percent change from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-11.4" spread="16.86"/>
                  <measurement group_id="O2" value="-11.3" spread="18.71"/>
                  <measurement group_id="O3" value="-11.2" spread="17.86"/>
                  <measurement group_id="O4" value="-11.3" spread="17.72"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Double Blind Period</title>
          <description>Placebo taken from day 1 to week 8.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Colesevelam Double Blind Period</title>
          <description>Low dose colesevelam 1.9 grams per day taken from day 1 to week 8.</description>
        </group>
        <group group_id="E3">
          <title>High Dose Colesevelam Double Blind Period</title>
          <description>High dose colesevelam 3.8 grams per day taken from day 1 to week 8.</description>
        </group>
        <group group_id="E4">
          <title>High Dose Colesevelam Open Label Extension</title>
          <description>All participants of the Open Label Extension (weeks 8-26) took colesevelam 3.8 grams per day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>renal hypoplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>poisoning deliberate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>nasopharyngeal cancer NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>diarrhea NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>upper respiratory infections NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>ear infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>gastrointestinal viral NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>rhinitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="184"/>
              </event>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="184"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reflects the following restrictive language in the Clinical Study Agreements: &quot;If identified by Daiichi Sankyo,Inc. (DSI), any of DSI's confidential information as defined herein shall be deletedNothing in this publication section shall be taken as giving DSI any right of editorial control over any publication prepared by the Study Site.&quot;</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Kessler</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>732-590-5032</phone>
      <email>hmkessler@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
